title: Augmentation of demineralized bone matrix (DBM) mineralization by a synthetic growth factor mimetic.
abstract: These studies evaluated whether F2A4-K-NS, a peptide mimetic of FGF-2, could augment ectopic bone production following the subcutaneous implant of human demineralized bone matrix (DBM). DBM was formulated into a gel with and without F2A4-K-NS, and injected subcutaneously into athymic rats. After 28 days the resultant tissue was excised and fixed. The tissue was examined with soft X-rays and microcomputerized tomography (micro-CT), and by histological methods. Inclusion of F2A4-K-NS with DBM resulted in an increased mineral deposition as determined by soft X-ray and micro-CT analysis and von Kossa staining. DBM-containing tissues showed extensive mineralization compared to the carrier alone, which was poorly mineralized. The mineralization was qualitatively and quantitatively the most extensive in the samples containing F2A4-K-NS plus DBM. Additionally, the highest amount of von Kossa staining for calcium was observed in tissues from animals that had received DBM plus F2A4-K-NS. In these studies, 100 ng of peptide per 0.2 mL of injectable DBM gel generated the most optimal results. The synthetic peptide F2A4-K-NS augmented DBM-induced ectopic mineralization in athymic animals.
authors.affiliation: Medical Department, Brookhaven National Laboratory, USA. xlin@biosetinc.com
authors.forename: Xinhua
authors.initials: X
authors.lastname: Lin
authors.forename: Louis A
authors.initials: LA
authors.lastname: Peña
authors.forename: Paul O
authors.initials: PO
authors.lastname: Zamora
authors.forename: Sarah L
authors.initials: SL
authors.lastname: Campion
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Takahashi
mesh_terms: D000818:Animals; D018775:Bone Demineralization Technique; D001857:Bone Matrix / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000637:transplantation; D018786:Bone Substitutes; D016025:Bone Transplantation; D002113:Calcification, Physiologic / Q000187:drug effects* / Q000502:physiology; D002118:Calcium / Q000032:analysis / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D006801:Humans; D008297:Male; D018919:Neovascularization, Physiologic / Q000187:drug effects / Q000502:physiology; D009842:Oligopeptides / Q000494:pharmacology*; D011859:Radiography; D051381:Rats; D011923:Rats, Nude; D013194:Staining and Labeling
chemical_list: D018786:Bone Substitutes; D009842:Oligopeptides; D016222:Fibroblast Growth Factor 2; D002118:Calcium